158 related articles for article (PubMed ID: 12084518)
1. Differential responsiveness of CRF receptor subtypes to N-terminal truncation of peptidic ligands.
Brauns O; Brauns S; Zimmermann B; Jahn O; Spiess J
Peptides; 2002 May; 23(5):881-8. PubMed ID: 12084518
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30.
Rühmann A; Bonk I; Lin CR; Rosenfeld MG; Spiess J
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15264-9. PubMed ID: 9860957
[TBL] [Abstract][Full Text] [Related]
3. Development of a selective photoactivatable antagonist for corticotropin-releasing factor receptor, type 2 (CRF2).
Bonk I; Rühmann A
Eur J Biochem; 2002 Nov; 269(21):5288-94. PubMed ID: 12392562
[TBL] [Abstract][Full Text] [Related]
4. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
Grigoriadis DE; Liu XJ; Vaughn J; Palmer SF; True CD; Vale WW; Ling N; De Souza EB
Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
[TBL] [Abstract][Full Text] [Related]
5. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
[TBL] [Abstract][Full Text] [Related]
6. Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity.
Jahn O; Tezval H; van Werven L; Eckart K; Spiess J
Neuropharmacology; 2004 Aug; 47(2):233-42. PubMed ID: 15223302
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells.
Kageyama K; Kimura R; Suga S; Ogawa Y; Suda T; Wakui M
Peptides; 2006 Jul; 27(7):1814-9. PubMed ID: 16513211
[TBL] [Abstract][Full Text] [Related]
8. Structure and function of the ovine type 1 corticotropin releasing factor receptor (CRF1) and a carboxyl-terminal variant.
Myers DA; Trinh JV; Myers TR
Mol Cell Endocrinol; 1998 Sep; 144(1-2):21-35. PubMed ID: 9863624
[TBL] [Abstract][Full Text] [Related]
9. Impact of N-terminal domains for corticotropin-releasing factor (CRF) receptor-ligand interactions.
Klose J; Fechner K; Beyermann M; Krause E; Wendt N; Bienert M; Rudolph R; Rothemund S
Biochemistry; 2005 Feb; 44(5):1614-23. PubMed ID: 15683245
[TBL] [Abstract][Full Text] [Related]
10. A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists.
Eckart K; Jahn O; Radulovic J; Tezval H; van Werven L; Spiess J
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11142-7. PubMed ID: 11572971
[TBL] [Abstract][Full Text] [Related]
11. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.
Lewis K; Li C; Perrin MH; Blount A; Kunitake K; Donaldson C; Vaughan J; Reyes TM; Gulyas J; Fischer W; Bilezikjian L; Rivier J; Sawchenko PE; Vale WW
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7570-5. PubMed ID: 11416224
[TBL] [Abstract][Full Text] [Related]
12. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain.
Primus RJ; Yevich E; Baltazar C; Gallager DW
Neuropsychopharmacology; 1997 Nov; 17(5):308-16. PubMed ID: 9348546
[TBL] [Abstract][Full Text] [Related]
13. Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity.
Brauns O; Brauns S; Jenke M; Zimmermann B; Dautzenberg FM
Peptides; 2002 Oct; 23(10):1817-27. PubMed ID: 12383870
[TBL] [Abstract][Full Text] [Related]
14. Identification of amino acids in the N-terminal domain of corticotropin-releasing factor receptor 1 that are important determinants of high-affinity ligand binding.
Wille S; Sydow S; Palchaudhuri MR; Spiess J; Dautzenberg FM
J Neurochem; 1999 Jan; 72(1):388-95. PubMed ID: 9886092
[TBL] [Abstract][Full Text] [Related]
15. Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin.
Gottowik J; Goetschy V; Henriot S; Kitas E; Fluhman B; Clerc RG; Moreau JL; Monsma FJ; Kilpatrick GJ
Neuropharmacology; 1997 Oct; 36(10):1439-46. PubMed ID: 9423932
[TBL] [Abstract][Full Text] [Related]
16. Involvement of the corticotropin-releasing factor (CRF) type 2 receptor in CRF-induced thyrotropin release by the amphibian pituitary gland.
Okada R; Miller MF; Yamamoto K; De Groef B; Denver RJ; Kikuyama S
Gen Comp Endocrinol; 2007 Feb; 150(3):437-44. PubMed ID: 17188689
[TBL] [Abstract][Full Text] [Related]
17. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
[TBL] [Abstract][Full Text] [Related]
18. Ligand requirements of the human corticotropin-releasing factor-binding protein.
Sutton SW; Behan DP; Lahrichi SL; Kaiser R; Corrigan A; Lowry P; Potter E; Perrin MH; Rivier J; Vale WW
Endocrinology; 1995 Mar; 136(3):1097-102. PubMed ID: 7867564
[TBL] [Abstract][Full Text] [Related]
19. A soluble form of the first extracellular domain of mouse type 2beta corticotropin-releasing factor receptor reveals differential ligand specificity.
Perrin MH; DiGruccio MR; Koerber SC; Rivier JE; Kunitake KS; Bain DL; Fischer WH; Vale WW
J Biol Chem; 2003 May; 278(18):15595-600. PubMed ID: 12611895
[TBL] [Abstract][Full Text] [Related]
20. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
Dautzenberg FM; Wille S
Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
